The latest update is out from Qualigen Therapeutics Inc (QLGN).
A Termination Agreement was finalized on March 25, 2024, ending a prior arrangement with Pan-RAS Holdings that would have allowed exclusive licensing and technology transfer of a RAS inhibitors drug development program. The original agreement, potentially beneficial for both parties, included a $1 million upfront fee and a share of sales royalties for RAS products. However, Pan-RAS Holdings failed to meet the closing deadline of March 16, 2024, resulting in the termination of the deal without liability to either side.
For an in-depth examination of QLGN stock, go to TipRanks’ Stock Analysis page.
